Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 10, 2006, Pages 917-924

  Harirforoosh, Sam ^a   Aghazadeh Habashi, Ali ^a   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cyclo oxygenase 2; Kidney; Non steroidal anti inflammatory drugs; Pharmacokinetics; Sodium urinary excretion

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ELECTROLYTE; MELOXICAM; MOBICOX; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; HUMAN; NEPHROTOXICITY; NONHUMAN; POTASSIUM EXCRETION; RAT; SINGLE DRUG DOSE; SODIUM URINE LEVEL; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; LACTONES; MALE; PLACEBOS; POTASSIUM; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM; SULFONAMIDES; SULFONES; THIAZINES; THIAZOLES;

EID: 33748901825     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04464.x     Document Type: Article

References (48)

1. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: Getting to the heart of the matter. J. Pharm. Pharm. Sci. 2004; 7: 332-6.
2. Fenton C, Keating GM, Wagstaff AJ. Valdecoxib: A review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. Drugs 2004; 64: 1231-61.
3. McMurray RW, Hardy KJ. Cox-2 inhibitors: Today and tomorrow. Am. J. Med. Sci. 2002; 323: 181-9.
4. Dequeker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol. 1998; 37: 946-51.
5. Hutchison R. COX-2-selective NSAIDs. Am. J. Nurs. 2004; 104: 52-5.
6. Brater DC. Renal effects of cyclooxygyenase-2-selective inhibitors. J. Pain Symptom Manage. 2002; 23 (Suppl.): S15-20.
7. Harirforoosh S, Jamali F. Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2/COX-1 selectivity on urinary sodium and potassium excretion in the rat. Can. J. Physiol. Pharmacol. 2005; 83: 85-90.
8. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension 2004; 43: 525-30.
9. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition. Am. J. Med. 1999; 107 (Suppl.): S65-70.
10. Alderman M, Sealey J, Cohen H, Madhavan S, Laragh J. Urinary sodium excretion and myocardial infarction in hypertensive patients: A prospective cohort study. Am. J. Clin. Nutr. 1997; 65 (Suppl.): S682-6.
11. Sandhu GK, Heyneman CA. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann. Pharmacother. 2004; 38: 700-4.
12. Canadian Pharmacists Association. Compendium of Pharmaceutical and Specialties. The Canadian Drug Reference for Health Professionals. Canadian Pharmacists Association, Ottawa. 2003.
13. Jamali F, Sattari S. High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma. J. Pharm. Pharm. Sci. 2000; 3: 312-17.
14. Guirguis MS, Sattari S, Jamali F. Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: Application of a novel HPLC assay. J. Pharm. Pharm. Sci. 2001; 4: 1- 6.
15. Velpandian T, Jaiswal J, Bhardwaj RK, Gupta SK. Development and validation of a new high-performance liquid chromatographic estimation method of meloxicam in biological samples. J. Chromatogr. B Biomed. Sci. Appl. 2000; 738: 431-6.
16. Bergerioux C, Kennedy G, Zikovosky L. Use of the semi-absolute method in neutron activation analysis. J. Radioanal. Chem. 1979; 50: 229-34.
17. Wyttenbach A. Coincidence losses in activation analysis. J. Radioanal. Chem. 1971; 8: 335-43.
18. Kim SW, Kim JW, Choi KC et al. Indomethacin enhances shuttling of aquaporin-2 despite decreased abundance in rat kidney. J. Am. Soc. Nephrol. 2004; 15: 2998-3005.
19. Szczepanska-Sadowska E, Paczwa P, Dobruch J. Enhanced food and water intake in renin transgenic rats. J. Physiol. Pharmacol. 2003; 54: 81-8.
20. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl Acad. Sci. USA 1999; 96: 7563-8.
21. Power I, Cumming AD, Pugh GC. Effect of diclofenac on renal function and prostacyclin generation after surgery. Br. J. Anaesth. 1992; 69: 451-6.
22. Murray MD, Lazaridis EN, Brizendine E, Haag K, Becker P, Brater DC. The effect of nonsteroidal antiinflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency. Am. J. Med. Sci. 1997; 314: 80-8.
23. Lee J, Kim SW, Jung TK et al. Indomethacin decreases particulate guanylyl cyclase activity in rat kidney. Clin. Exp. Pharmacol. Physiol. 2004; 31: 207-11.
24. Sellers RS, Senese PB, Khan KN. Interspecies differences in the nephrotoxic response to cyclooxygenase inhibition. Drug Chem. Toxicol. 2004; 27: 111-22.
25. Khan KN, Venturini CM, Bunch RT et al. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in non-steroidal antiinflammatory drug-related nephrotoxicity. Toxicol. Pathol. 1998; 26: 612-20.
26. Komhoff M, Jeck ND, Seyberth HW, Grone HJ, Nusing RM, Breyer MD. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int. 2000; 58: 2420-4.
27. Vio CP, Cespedes C, Gallardo P, Masferrer JL. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997; 30: 687-92.
28. 2 inhibits oxygen consumption in rabbit medullary thick ascending limb. Am. J. Physiol. 1990; 258: F1372-8.
29. Catella-Lawson F, McAdam B, Morrison BW et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 1999; 289: 735-41.
30. Tan SY, Shapiro R, Franco R, Stockard H, Mulrow PJ. Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism. Ann. Intern. Med. 1979; 90: 783-5.
31. Braden GL, O'Shea MH, Mulhern JG, Germain MJ. Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol. Dial. Transplant. 2004; 19: 1149-53.
32. Breyer MD, Harris RC. Cyclooxygenase 2 and the kidney. Curr. Opin. Nephrol. Hypertens. 2001; 10: 89-98.
33. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: Effects on kidney function. J. Clin. Pharmacol. 1991; 31: 588-98.
34. Moutabarrik A, Ishibashi M, Kameoka H et al. In vitro FK506 kidney tubular cell toxicity. Transpl. Int. 1992; 5 (Suppl.): S87-92.
35. PereZ. M, Castilla M, Torres AM, Lazaro JA, Sarmiento E, Tejedor A. Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. Nephrol. Dial. Transplant. 2004; 19: 2445-55.
36. Dellinger P, Murphy T, Pinn V, Barza M, Weinstein L. Protective effect of cephalothin against gentamincin-induced nephrotoxicity in rats. Antimicrob. Agents Chemother. 1976; 9: 172-8.
37. Schentag JJ, Jusko WJ, Plaut ME, Cumbo TJ, Vance JW, Abrutyn E. Tissue persistence of gentamicin in man. JAMA 1977; 238: 327-9.
38. Schentag JJ, Cumbo TJ, Jusko WJ, Plaut ME. Gentamicin tissue accumulation and nephrotoxic reactions. JAMA 1978; 240: 2067-9.
39. Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin. Pharmacokinet. 1987; 12: 402-32.
40. Halpin RA, Geer LA, Zhang KE et al. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metab. Dispos. 2000; 28: 1244-54.
41. Paulson SK, Kaprak TA, Gresk CJ et al. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm. Drug Dispos. 1999; 20: 293-9.
42. Busch U, Schmid J, Heinzel G et al. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab. Dispos. 1998; 26: 576-84.
43. Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003; 4: E33.
44. Laska EM, Sunshine A, Marrero I, Olson N, Siegel C, McCormick N. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin. Pharmacol. Ther. 1986; 40: 1- 7.
45. Jamali F, Kunz-Dober CM. Pain-mediated altered absorption and metabolism of ibuprofen: An explanation for decreased serum enantiomer concentration after dental surgery. Br. J. Clin. Pharmacol. 1999; 47: 391-6.
46. Day RO, Furst DE, Dromgoole SH, Kamm B, Roe R, Paulus HE. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin. Pharmacol. Ther. 1982; 31: 733-40.
47. Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin. Pharmacokinet. 1990; 19: 197-217.
48. Vakily M, Khorasheh F, Jamali F. Dependency of gastrointestinal toxicity on release rate of tiaprofenic acid: A novel pharmacokinetic-pharmacodynamic model. Pharm. Res. 1999; 16: 123-9.